Recent advances in statins and the kidney

Kidney International, Supplement

Volumn 56, Issue 71, 1999, Pages

  Oda, Hiroaki ^a   Keane, William F ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Apolipoprotein; Dyslipidemia; Fibrinogen; Lipid lowering agents

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPID; LIPOPROTEIN; STATIN; HYPOCHOLESTEROLEMIC AGENT;

CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DYSLIPIDEMIA; FIBROGENESIS; INFLAMMATION; KIDNEY DISEASE; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MACROPHAGE ACTIVATION; PRENYLATION; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; ANIMAL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY; PATHOLOGY; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KIDNEY; KIDNEY DISEASES;

EID: 0032976460     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. KASISKE BL, O'DONNELL MP, GARVIS WJ, KEANE WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62:367-374, 1988
2. O'DONNELL MP, KASISKE BL, KIM Y, SCHMITZ PG, KEANE WF: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22:83-89, 1993
3. O'DONNELL MP, KASISKE BL, KATZ SA, SCHMITZ PG, KEANE WF: Lovastatin but not enalapril reduces glomerular injury in Dahl salt-sensitive rats. Hypertension 20:651-658, 1992
4. HARRIS KP, PURKERSON ML, YATES J, KLAHR S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 15:16-23, 1990
5. GILE RD, COWLEY BD JR, GATTONE VH II, O'DONNELL MP, SWAN SK, GRANTHAM JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 26:501-507, 1995
6. IAINA A, BENYAMIN G, LEVTOV O, GETTER R, SERBAN I, WOLLMAN Y, RUBINSTEIN A, CABILI S, PEER G, BLUM M: Effect of chronic cholesterol loading in the development of acute ischemic renal failure in rats. Renal Fail 16:117-123, 1994
7. JIANG J, ROMAN RJ: Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension 30:968-974, 1997
8. YOSHIMURA A, INUI K, NEMOTO T, UDA S, SUGENOYA Y, WATANABE S, YOKOTA N, TAIRA T, IWASAKI S, IDEURA T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 9:2027-2039, 1998
9. KASISKE BL, O'DONNELL MP, KIM Y, ATLURU D, KEANE WF: Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis. Kidney Int 45(Suppl 45):S51-S53, 1994
10. KEANE WF, KASISKE BL, O'DONNELL MP, KIM Y: The role of altered lipid metabolism in the progression of renal disease: Experimental evidence. Am J Kidney Dis 17(Suppl 1):38-42, 1991
11. GUIJARRO C, KEANE WF: Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 2:372-379, 1993
12. PESEK-DIAMOND I, DING G, FRYE J, DIAMOND JR: Macrophages mediate adverse effects of cholesterol feeding in experimental nephrosis. Am J Physiol 263:F776-F783, 1992
13. ROVIN BH, TAN LC: LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43:218-225, 1993
14. SATRIANO JA, HORA K, SHAN Z, STANLEY ER, MORI T, SCHLONDORFF D: Regulation of monocyte chemoattractant protein-1 and macrophage colony-stimulating factor-1 by IFN-γ, tumor necrosis factor-α, IgG aggregates, and cAMP in mouse mesangial cells. J Immunol 150:1971-1978, 1993
15. MORI T, BARTOCCI A, SATRIANO J, ZUCKERMAN A, STANLEY R, SANTIAGO A, SCHLONDORFF D: Mouse mesangial cells produce colony-stimulating factor-1 (CSF-1) and express the CSF-1 receptor. J Immunol 144:4697-4702, 1990
16. KIM SY, GUIJARRO C, O'DONNELL MP, KASISKE BL, KIM Y, KEANE WF: Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int 48:363-371, 1995
17. PARK YS, GUIJARRO C, KIM Y, MASSY ZA, KASISKE BL, KEANE WF, O'DONNELL MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-194, 1998
18. GUIJARRO C, KEANE WF: Effects of lipids on the pathogenesis of progressive renal failure: Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis. Miner Electrolyte Metab 22:147-152, 1996
19. GUIJARRO C, KIM Y, SCHOONOVER CM, MASSY ZA, O'DONNELL MP, KASISKE BL, KEANE WF, KASHTAN CE: Lovastatin inhibits lipopolysaccharide-induced NF-κB activation in human mesangial cells. Nephrol Dial Transplant 11:990-996, 1996
20. KEANE WF, O'DONNELL MP, KASISKE BL, KIM Y: Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 4:187-194, 1993
21. NISHIDA Y, YORIOKA N, ODA H, YAMAKIDO M: Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 29:919-930, 1997
22. NISHIDA Y, YORIOKA N, ODA H, ASAKIMORI Y, AMIMOTO D, YAMAKIDO M: Intermediate-density lipoprotein is a DNA synthesis stimulation factor in cultured human mesangial cells. Nephron 73:334-335, 1996
23. O'DONNELL MP, KASISKE BL, KIM Y, ATLURU D, KEANE WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91:83-87, 1993
24. GRANDALIANO G, BISWAS P, CHOUDHURY GG, ABBOUD HE: Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44:503-508, 1993
25. VRTOVSNIK F, COUETTE S, PRIÉ D, LALLEMAND D, FRIEDLANDER G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int 52:1016-1027, 1997
26. ROGLER G, LACKNER KJ, SCHMITZ G: Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 76:114A-116A, 1995
27. MUNRO E, PATEL M, CHAN P, BETTERIDGE L, CLUNN G, GALLAGHER K, HUGHES A, SCHACHTER M, WOLFE J, SEVER P: Inhibition of human vascular smooth muscle cell proliferation by lovastatin: The role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 24:766-772, 1994
28. HIDAKA Y, EDA T, YONEMOTO M, KAMEI T: Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 95:87-94, 1992
29. CHAKRABARTI R, ENGLEMAN EG: Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biol Chem 266:12216-12222, 1991
30. GRIECO D, BEG ZH, ROMANO A, BIFULCO M, ALOJ SM: Cell cycle progression and 3-hydroxy-3-methylglutaryl coenzyme A reductase are regulated by thyrotropin in FRTL-5 rat thyroid cells. J Biol Chem 265:19343-19350, 1990
31. BARBU V, DAUTRY F: Mevalonate deprivation alters the induction of fos and myc by growth factors. Oncogene 5:1077-1080, 1990
32. FUKADA Y, TAKAO T, OHGURO H, YOSHIZAWA T, AKINO T, SHIMONISHI Y: Farnesylated g-subunit of photoreceptor G protein indispensable for GTP-binding. Nature 346:658-660, 1990
33. QIU MS, PITTS AF, WINTERS TR, GREEN SH: Ras isoprenylation is required for ras-induced but not for NGF-induced neuronal differentiation of PC12 cells. J Cell Biol 115:795-508, 1991
34. REISS Y, STRADLEY SJ, GIERASCH LM, BROWN MS, GOLDSTEIN JL: Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sci USA 88:732-736, 1991
35. ISHIKAWA S, KAWASUMI M, SAITO T: Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinology 136:1954-1961, 1995
36. GHOSH PM, MOTT GE, GHOSH-CHOUDHURY N, RADNIK RA, STAPLETON ML, GHIDONI JJ, KREISBERG JI: Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. Biochim Biophys Acta 1359:13-24, 1997
37. GUIJARRO C, BLANCO-COLIO LM, ORTEGO M, ALONSO C, ORTIZ A, PLAZA JJ, DÍAZ C, HERNÁNDEZ G, EDIGO J: 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 83:490-500, 1998
38. HENGST L, DULIC V, SLINGERLAND JM, LEES E, REED SI: A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 91:5291-5295, 1994
39. HENGST L, REED SI: Translational control of p27Kipl accumulation during the cell cycle. Science 271:1861-1864, 1996
40. HIRAI A, NAKAMURA S, NOGUCHI Y, YASUDA T, KITAGAWA M, TATSUNO I, OEDA T, TAHARA K, TERANO T, NARUMIYA S, KOHN LD, SAITO Y: Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kipl and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells. J Biol Chem 272:13-16, 1997
41. ODA H, KASISKE BL, O'DONNELL MP, KEANE WF: Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Kidney Int 56(Suppl 71):S-202-S-205, 1999
42. O'DRISCOLL G, GREEN D, TAYLOR RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95:1126-1131, 1997
43. HERNÁNDEZ-PERERA O, PEREZ-SALA D, NAVARRO-ANTOLIN J, SANCHEZ-PASCUALA R, HERNANDEZ G, DÍAZ C, LAMAS S: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101:2711-2719, 1998
44. EGASHIRA K, HIROOKA Y, KAI H, SUGIMACHI M, SUZUKI S, INOU T, TAKESHITA A: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89:2519-2524, 1994
45. TREASURE CB, KLEIN JL, WEINTRAUB WS, TALLEY JD, STILLABOWER ME, KOSINSKI AS, ZHANG J, BOCCUZZI SJ, CEDARHOLM JC, ALEXANDER RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332:481-487, 1995
46. OSAMAH H, MIRA R, SORINA S, SHLOMO K, MICHAEL A: Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. Br J Clin Pharmacol 44:77-83, 1997